Trial Profile

A retrospective, observational study analysing real-world dosing, management, and clinical outcomes of patients (pts) with metastatic pancreatic adenocarcinoma (mPDA) treated with liposomal irinotecan

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 May 2021 Results (n=608) assessing clinical characteristics and treatment outcomes based on race, presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
17 Jan 2021 Results of one-year overall survival presented at the 2021 Gastrointestinal Cancers Symposium
21 Sep 2020 Results (n=348) assessing the survival outcomes associated with DRs among pts with mPDAC treated with liposomal irinotecan presented at the 45th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com